Form 4: Bicycle Therapeutics Insider Sells Shares

Michael Hannay, Chief Prod & Supply Chain Officer at Bicycle Therapeutics PLC, reported the sale of 1,521 ordinary shares on April 2, 2026, and an additional 251 shares on April 6, 2026.

Summary

• Michael Hannay, Chief Prod & Supply Chain Officer at Bicycle Therapeutics PLC, has reported transactions involving the sale of ordinary shares.
• On April 2, 2026, 1,521 ordinary shares were sold at a weighted average price of $4.91, with individual sales ranging from $4.88 to $4.98.
• On April 6, 2026, an additional 251 ordinary shares were sold at a price of $5.05.
• These sales were part of a 'sell to cover' transaction to satisfy statutory tax withholding obligations related to the vesting and settlement of RSUs, as mandated by the reporting person's award agreement.
• Following these transactions, Mr. Hannay beneficially owns 96,136 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported sales are mandated for tax purposes and do not necessarily reflect a negative view on the company's future by the insider.

Negatives

• Insider selling activity, even if for tax purposes, can sometimes be perceived negatively by the market.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to insider transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. While this filing details a 'sell to cover' for tax obligations, any insider selling can be a point of observation for investors monitoring management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders: The sale of shares by an insider, even for tax reasons, may lead to short-term market scrutiny, though the mandated nature of the sale mitigates concerns about insider confidence.

Key Dates

Keywords

Form 4, Insider Transaction, Bicycle Therapeutics, Share Sale, RSU Vesting, Tax Withholding, Michael Hannay